Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.

Frontiers in immunology - 1 Jan 2020

Boutros Andrea, Schiavi Chiara, Cecchi Federica, Spagnolo Francesco, Guadagno Antonio, Tanda Enrica Teresa, Giusti Francesca, Murdaca Giuseppe, Queirolo Paola

Abstract excerpt

Adjuvant treatment of operated melanoma has deeply changed in the last few years with the introduction of immune-checkpoint inhibitors and BRAF/MEK inhibitors. Sarcoidosis is a systemic inflammatory disease causing non-caseous granulomatous reactions. Sarcoid-like granulomatous reactions have been reported in patients with advanced melanoma, mostly related to immunotherapy with immune-checkpoint inhibitors. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Kinase Kinases

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Sarcoidosis

Source

Open in PubMed Open full text

Identifiers

PMID: 33312171
DOI: 10.3389/fimmu.2020.579523
PMCID: PMC7704616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.PMID 33312171Read ↗

BRAF inhibition and the spectrum of granulomatous reactions.Semantic proximity Read ↗

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.Semantic proximity Read ↗

Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.Semantic proximity Read ↗

Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.Semantic proximity Read ↗

Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosisSemantic proximity Read ↗

Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.Semantic proximity Read ↗

BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series.Semantic proximity Read ↗

Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.Semantic proximity Read ↗

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.Semantic proximity Read ↗

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.Semantic proximity Read ↗

Research letter: BRAF-inhibitor induced panniculitis - A systematic review.Semantic proximity Read ↗

Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.